Rett syndrome: The silent thief of childhood skills

Rett syndrome (RTT) is a complex neurodevelopmental disorder primarily affecting females, with an incidence of 1 in 10,000 to 15,000. It is characterized by a period of normal development followed by a regression of acquired skills. Typical symptoms include deceleration in head growth, gait abnormalities, loss of purposeful hand movements, often replaced by repetitive hand-wringing, loss of speech, and breathing irregularities.
The majority of RTT cases (about 90%) are linked to mutations in the methyl-CpG-binding protein 2 (MECP2) gene, with other cases involving mutations in CDKL5 and FOXG1. These genetic mutations impact neuronal development and function, leading to the observed clinical features. Diagnosis is primarily clinical, based on the characteristic symptoms and progression, with genetic testing for MECP2 mutations providing confirmation. Management of RTT requires a multidisciplinary approach, addressing the various medical issues such as seizures, behavioral changes, sleep disturbances, cardiac irregularities, gastrointestinal problems, and skeletal abnormalities. Although there is no cure for RTT, symptomatic treatments, including antiepileptic drugs for seizures and SSRIs for behavioral issues, significantly improve quality of life.
Emerging research is focusing on the underlying genetic mechanisms and potential therapeutic targets. Advances in understanding the pathophysiology of RTT and the role of MECP2 in brain development may pave the way for more effective treatments and possibly a cure.